Envista
DEXIS™IS ScanFlow v.1.0.10 adds new series of guided workflows and AI enhancements to optimize the dental implant workflow.
QUAKERTOWN, PA / ACCESSWIRE / March 19, 2024 / Earlier this year, DEXIS launched its dental implant ecosystem so clinicians can manage their entire implant workflow, from diagnosis to delivery, with one integrated toolset. To enhance workflow efficiencies, DEXIS announces the release of a new intraoral scanning update, DEXIS™IS ScanFlow v.1.0.10. The update includes a new series of guided workflows, enhancements to its AI capabilities, and an integration with DEXIS Imaging Suite software version 10.
"We are excited to introduce our latest DEXIS intraoral scanning software update, aimed at boosting productivity for DEXIS software owners and implant workflows," says Brian Gooch, VP of Marketing at DEXIS. "We've made scanning fast and easy, even for more complex situations. Digital impression data is important for implant case planning, so we enable highly accurate data to be incorporated into chairside or open workflows, and easily shared with labs or colleagues."
The IS ScanFlow software update maintains high-speed scanning, user-friendly interface, precise data capture, and an open, flexible system. Early adopters have provided positive feedback, highlighting the system's ease of use and its ability to reliably capture accurate data.
Early adopters have reported positive feedback, highlighting the wide range of cases they're able to accurately capture data for:
"The DEXIS IS 3800W intraoral scanner and its predecessors have enabled me to apply digital dentistry to all my prosthetic and implant cases," says Dr. Sebastian Patzelt. "Now, with the new AI applications in DEXIS IS ScanFlow, I'm able to digitize the soft and hard tissues of the oral cavity for fixed, removable or implant cases accurately and efficiently. *"
IS ScanFlow v1.0.10 aims to maximize productivity through AI-driven tools for dentists.
The new release adds a brand-new AI Matching tool that simplifies data capture in complex situations like multiple scan bodies, full and partial edentulism.
It also includes algorithm enhancements to its Implant Scan Body AI Assist tool which automatically detects scan bodies and reduces noise in the data, corrects artifacts and enhances details - furthering the automation of precise data capture.
IS ScanFlow v 1.0.10 introduces guided dental workflows to cut manual tasks and simplify processes.
Users now have the flexibility to fill out case information before initiating scanning or after completion, thanks to the new CaseFlow Manager tool. Regardless of the chosen option, users can then move into an easy, guided workflow that automates manual processes, predicts next steps, and assists in acquiring data for the selected indication.
The brand-new Full Arch Implant workflow guides users through the data-capture workflow for a full arch case and then automatically aligns the scans in occlusion, allowing for one consolidated dataset to send to a lab or manufacturer.
IS ScanFlow v 1.0.10 also facilitates efficient lab communication by enabling users to view case progress and real-time lab status updates directly within the Patient History screen. This allows easy collaboration, reduction in delays, and timely completion of tasks.
IS ScanFlow integrates with DTX Studio™ Clinic to connect the implant workflow
"The true power of IS ScanFlow is seen when paired with the core of the DEXIS implant ecosystem-DTX Studio Clinic," says Brian Gooch, VP of Marketing at DEXIS. "Packed with smart tools and advanced algorithms, DTX Studio Clinic serves as the clinic's imaging homebase, diagnostic hub, and treatment planning navigator. It connects each step of the implant process together and now, when purchased with an intraoral scanner, comes at no extra cost.
"Implant workflow productivity can be maximized by integrating IS ScanFlow into the rest of the tools and software within the DEXIS digital ecosystem - where practices can manage an entire implant case, from diagnosis to delivery, with one integrated toolset."
To learn more about DEXIS and the latest IS ScanFlow software version, visit https://www.dexis.com.
About DEXIS
DEXIS has been a global leading brand in digital radiography for 70+ years. Today, DEXIS has brought together the most trusted brands in 3D imaging, intraoral scanning solutions, and diagnostic software to provide patients with a complete digital diagnostic solution under a brand name. Our innovative award-winning technology enhances how the patient is diagnosed, accelerates the workflow, and delivers simple treatment paths with better patient outcomes. For more information, please visit https://www.dexis.com.
*Dr. Robert Pauley is a paid consultant for DEXIS
Contact Information
Hayley Reed
Regional Marketing Director, DEXIS IOS
hayley.reed@envistaco.com
(714) 628-8533
SOURCE: DEXIS
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom